|
Video: What is a Stock Split?
|
|
ImmunoGen is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs). Co.'s main program is mirvetuximab, an ADC targeting folate receptor alpha, a cell-surface protein overexpressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Pivekimab sunirine is an ADC comprised of an antibody designed to target CD123 with site-specific conjugation to a DNA-alkylating payload of the IGN (indolinobenzodiazepine pseudodimer) class. Co.'s pipeline program, IMGC936, is an ADC that is designed to target ADAM9, an enzyme overexpressed in a range of solid tumors and implicated in tumor progression and metastasis. According to our Immunogen Inc - Comm stock split history records, Immunogen Inc - Comm has had 0 splits. | |
|
Immunogen Inc - Comm (IMGN) has 0 splits in our Immunogen Inc - Comm stock split history database.
Looking at the Immunogen Inc - Comm stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Immunogen Inc - Comm shares, starting with a $10,000 purchase of IMGN, presented on a split-history-adjusted basis factoring in the complete Immunogen Inc - Comm stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/29/2014 |
|
End date: |
02/12/2024 |
|
Start price/share: |
$12.99 |
|
End price/share: |
$31.23 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
140.42% |
|
Average Annual Total Return: |
9.37% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$24,048.94 |
|
Years: |
9.80 |
|
|
|
|
|